Summit Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview

Summit Therapeutics

29/04/2025 21:06

Summit Therapeutics Inc SMMT.OQ SMMT.O is expected to show no change in quarterly revenue when it reports  results on May 1 for the period ending March 31 2025

​LSEG's mean analyst estimate for Summit Therapeutics Inc is for a loss of 9 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Summit Therapeutics Inc is $36.00​, above​ its last closing price of $24.11. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.08
-0.08
-0.08
Met
1.8
Sep. 30 2024
-0.06
-0.07
-0.08
Missed
-20
Jun. 30 2024
-0.06
-0.06
-0.09
Missed
-45.2​
Mar. 31 2024
-0.06
-0.06
-0.06
Met
0
​​
​

This summary was machine generated April 29 at 20:06 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)